The Share

The Diamyd Medical share is traded on Nasdaq First North (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North

Nasdaq First North is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399.

Annual Report

  November 3, 2016
  Financial Statement, October 11, 2017

Dear Shareholders and readers

Given the strategic decisions taken over the past year and the company’s strong cash position following the successful new share issue this spring, we have significantly accelerated our operations during the quarter.
During the quarter national competent authorities from all of the participating countries (Spain, Sweden and Czech Republic) approved the conduction of the DIAGNODE-2 trial. The Investigator Meeting we arranged last week in Barcelona, at which the trial protocol was...

We have made an ambitious achievement moving the DIAGNODE-2 trial forward on an aggressive timeline.
Ulf Hannelius, President and CEO

Event Calendar

 Dates for financial information and other events
November 6, 2017
Bio-Europe 2017
23rd annual BIO-Europe conference, 6-8 November, Berlin, Germany
November 13, 2017
Stora Aktiedagen
Event by Aktiespararna, Hotel Birger Jarl, Stockholm
November 30, 2017
Annual General Meeting

Financial Calendar

 November 9, 2017
Annual Report 2016/2017
 November 30, 2017
 January 24, 2018
Quarterly Report 1 2016/2017
 March 28, 2018
Quarterly Report 2 2017/2018
 June 27, 2018
Quarterly Report 3 2017/2018
 October 10, 2018
Financial statement 2017/2018
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of July 31, 2017

ShareholderA SharesB SharesCapital %Votes %
Essen-Möller, Anders 2 130 186 6 110 867 14.63 36.31
Avanza Pension 7 076 877 12.56 9.37
Lindkvist, Bertil 6 056 858 10.75 8.02
Nordnet Pensionsförsäkring AB 2 419 911 4.30 3.20
Swedbank Försäkring 672 980 1.19 0.89
Relbo AB 396 292 0.70 0.52
Försäkrings AB Skandia 350 874 0.62 0.46
Arandi Development AB 350 000 0.62 0.46
Wellwing, Stig 350 000 0.62 0.46
Bohlin, Lennart 345 571 0.61 0.46
Remaining shareholders 30 073 488 53.4 39.8
Total 2 130 186 54 203 718 100.0 100.0